Corgenix Medical turns quarterly profit
Broomfield-based Corgenix (OTC BB: CONX) reported a 20 percent increase in revenue to $2.5 million for the most recent quarter, according to a company earnings statement. Revenue was $2.1 million for the same quarter in 2011, the company said.
Corgenix's profit for the quarter was $55,755 compared with an operating loss of $56,722 for the same quarter a year ago, according to the earnings statement.
AspirinWorks is the only U.S. test cleared by the Food and Drug Administration that measures a biomarker in urine to determine aspirin's effects in apparently healthy individuals. The test targets a potential global market of more than 200 million people, the company has said in the past.
AspirinWorks accounted for 16.2 percent of Corgenix's overall sales in 2012, according to Securities and Exchange Commission filings. Corgenix also makes and sells more than 50 other diagnostic products to test patients for immunology disorders, vascular diseases and bone and joint disorders.
More breaking news...
Boulder County posts state-low foreclosures
Tickets on sale for BCBR's Mercury 100
Across Colorado, the average was about 1 completed foreclosure sale
The list of 100